ClinicalTrials.gg
RecruitingNCT06797726ADHDDICTUpdated Jun 25, 2025

Feasibility and Efficacy of Cognitive-Behavioral Therapy for Patients With ADHD/Behavioral Addiction Comorbidity

An interventional study of Cognitive behavioral therapy in ADHD and Behavioral Addiction, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by University Hospital, Tours · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France — 20 open to participants now, 20 under way, 2 of them phase 3. Attention Deficit Disorder with Hyperactivity · France.

Planned enrollment
39th of 60
54 · median 80
Started
2025
with 5 others
No phase
42 of 82
12 open now
Primary completion
2026-08
later than 4 of 19 live
Registered
71st of 82
by date

Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, this one is the 39th largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 42 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 71st registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

20 of the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, or all of them as a file.
02

Study summary

The main objective of this pilot study is to assess preliminary data on the feasibility of CBT and its evaluation in a randomised trial in patients with co-occurring ADHD and behavioural addiction: Evaluation and comparison of the 12-week retention rate of patients randomised to CBT compared with patients in the 'treatment as usual' control arm.

In order to meet the objective, the patient will take part in a standardized assessment, followed by a therapeutic intervention and a new standardized assessment after the intervention. The standardized assessment consists as follows :

  • firstly, 7 self-questionnaires to be completed by the patient, lasting around 45 min, aimed at assessing his or her socio-demographic data; current symptoms, quality of life and functional impact related to ADHD; impulsivity, emotion regulation and assessment of possible anxiety-depressive disorders.
  • Then the patient will follow the 10 session of cognitivo behavioural psychotherapy.
  • At 12-weeks post-inclusion, an assessment visit is carried out during which a battery of tests will be administered. This is followed by a research interview with a professional, aimed at gathering his or her experiences.
03

Conditions studied

  • ADHD
  • Behavioral Addiction

Keywords

  • CBT
  • Cognitive behavioral therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 (age ≥ 18 years)
  • Patient treated in an outpatient addictology department at the CHU of Brest, Nantes or Tours and presenting an ADHD/behavioral addiction comorbidity
  • Patient affiliated to a social security scheme
  • For patients treated with methylphenidate: no change in treatment dosage during the previous three months.
  • For patients not treated with methylphenidate: no introduction of methylphenidate within the next three months.

Exclusion criteria

Exclusion Criteria:

  • Patients with psychotic disorders (assessed by clinician)
  • Pregnant or breast-feeding women
  • Patients under protective supervision (guardianship or curatorship)
  • Persons under court protection
  • Persons deprived of their liberty
  • Patients who do not meet the eligibility criteria for CBT (e.g., cognitive impairment, hearing impairment).
  • Physical inability to participate in CBT sessions (e.g., lack of telephone, foreseeable unavailability).
  • Difficulty understanding self-questionnaires, including illiteracy.
  • Participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    CBT group

    10 sessions of Cognitive Behavioral Therapy (CBT) Behavioral and Cognitive Therapy (CBT) adapted to comorbidity ADHD/behavioral addiction in remote format (teleconsultation) + routine care (care provided according to the protocols of each center).

    Behavioral: Cognitive behavioral therapy

  • No intervention
    Control group

    routine care (care performed according to protocols of each center)

Interventions

  • BehavioralCognitive behavioral therapy

    Session 1: Functional analysis, motivational approach and psycho-education (advantages/disadvantages of consumption ; effect of addiction on mental disorders and interaction ADHD/behavioral addiction) Session 2: Follow-up to psycho-education session 1, treatment plan Session 3: ADHD: compensation strategies; reducing distractibility distractibility Session 4: ADHD: calendar and organization worksheet Session 5: ADHD: mood disorders and emotions Session 6: Recognizing and managing emotions Session 7: Analysis of functional elements in addictive disorder addictive disorders in patients with ADHD Session 8: Risk situations, psycho-education (emotions) Session 9: Managing craving; analysis of the functional elements of of addiction Session 10: Relapse and relapse prevention, problem solving and social pressure

06

What researchers measure

Primary outcomes

  1. Retention rate

    Proportion of randomized present at the 12-week visit

    Time frame: At the 12-week

  2. Adhesion

    Number of sessions performed between baseline and 12 weeks,

    Time frame: Between baseline and 12 weeks

  3. Adhesion

    percentage of patients who attended at least 70% of sessions

    Time frame: between baseline and 12 weeks

Secondary outcomes

  1. Quantitative evaluation of acceptance percentage

    Number of randomized patients / number of eligible patients eligible patients

    Time frame: At 14 weeks

  2. Satisfaction of participants in the Cognitive-behavioural therapy group

    only assessed in Cognitive-behavioural therapy group, assessed during an interview with a psychologist (qualitative evaluation)

    Time frame: At 14 weeks

  3. Perceived benefits

    only assessed in Cognitive-behavioural therapy group, assessed during an interview with a psychologist

    Time frame: At 14 weeks

  4. Collection of difficulties during the therapy

    only assessed in Cognitive-behavioural therapy group, assessed during an interview with a psychologist

    Time frame: At 14 weeks

  5. Assessment of barriers and levers to psychotherapy and cognitive behavioral disorder therapy

    Evaluated only for the control group, assessed during an interview with a psychologist

    Time frame: At 14 weeks

  6. Assessment of patients' perceived needs in terms of psychotherapy

    Evaluated only for the control group, assessed during an interview with a psychologist

    Time frame: At 14 weeks

  7. ADHD symptoms

    Evaluation will be based on the ASRS-18 (Adult Self-Report Scale) total score. This self-administered questionnaire comprises eighteen questions, six of which are considered to be the most representative of the symptoms associated with ADHD. These six questions, in Part A of the questionnaire, form the core of the ASRS v1.1 screening. Part B contains the remaining twelve questions. The impact of symptoms on different areas of the patient's life is also assessed. Screening is positive when the patient presents at least 4 symptoms with a significant impact among the first 6 items . Each item is rated from 0 to 4, giving a total ASRS-18 score ranging from 0 to 72, with sub-scores for inattention (0 to 36), motor hyperactivity/impulsivity (0 to 20) and verbal hyperactivity/impulsivity (0 to 16).

    Time frame: From baseline up to 12 weeks

  8. Quality of life specific to attention-deficit disorder (ADHD)

    The Adult ADHD Quality of Life scale (AAQOL) will be used during the assessment phases. This tool has good psychometric qualities and assesses four dimensions of quality of life: productivity in daily life, psychological health, relationships and outlook on life. The AAQOL provides a total quality of life score, as well as 4 sub-scores for each dimension. The total score is between 0 and 100, the sub-dimension scores between 0 and 100 (transformed from responses to each of the responses to each of the 29 items ranging from 1 to 5). The higher the score (total and sub-score), the higher, the better the quality of life

    Time frame: From baseline up to 12 weeks

  9. Functional impact of attention deficit hyperactivity disorder (ADHD)

    The Weiss Functional Impairment Rating Scale-Self-Report (WFIRS-S) will be used during the assessment phases. This tool, with good psychometric qualities, assesses the impacts of ADHD in seven domains: family, work life, school life, life skills, self-image, social life and risk-taking. Any item rated "2" or "3" is two standard deviations outside the clinical norms for ADHD and is considered impaired. A conservative threshold for defining impairment in any domain is either two items scored '2', or one item scored '3'. The average item score for most domains is '1', with the exception of 'at-risk activities', which is '0.5'. The average score for each of the 7 dimensions is between 0 and 3.

    Time frame: From baseline up to 12 weeks

  10. Craving

    A visual analog scale (VAS) to assess craving will be used. In the absence of a validated tool to measure craving in a homogeneous way in behavioral addictions, we will ask participants to rate the intensity of craving on a scale from 0 to 10 (0 corresponding to no craving and 10 to maximum craving) and to evaluate the frequency of craving as well as its duration. This type of craving measurement is frequently used in the literature and in addiction research protocols.

    Time frame: From baseline up to 12 weeks

  11. Impulsivity

    The Impulsive Behavior Scale (UPPS-P) will be used during the assessment phases to measure impulsivity. This tool has good psychometric qualities and measures the following sub-dimensions of impulsivity: positive urgency, negative urgency, lack of premeditation, lack of perseverance and sensation seeking. The score for each dimension ranges from 4 to 16; there is no total score. The higher the score (subscales), the higher the impulsivity.

    Time frame: From baseline up to 12 weeks

  12. Emotional dysregulation

    The Difficulties in Emotion Regulation Scale (DERS 36) will be used (during the assessment phases) to evaluate emotional dysregulation. With good psychometric qualities, this scale measures 6 dimensions: unacceptance of negative emotions, difficulty engaging in goal-directed behaviors in the presence of negative emotions, difficulty controlling impulsive behaviors in the presence of negative emotions, restricted access to emotion regulation strategies perceived as effective, emotional awareness and lack of understanding of one's emotions, defined as a lack of emotional clarity. The total score ranges from 36 to 180, with sub-dimensions scores ranging from 6 to 30. The higher the score (total scale and subscales), the greater the emotional dysregulation.

    Time frame: From baseline up to 12 weeks

  13. Anxiety symptoms

    The Hospital Anxiety and Depression scale (HAD) will be used to assess the presence of anxiety and depressive symptoms in participants. This is a variable we wish to control for, in order to verify that anxiety and depressive symptoms are not potential confounding factors in the assessment results. This scale has good psychometric qualities and can be used to assess two dimensions: anxiety symptoms and depressive symptoms. The total score ranges from 0 to 21 for each dimension. For each dimension, the following interpretation can be proposed: \- 7 or less: no symptoms - 8 to 10: moderate score - 11 to 14: average score 15 to 21: severe score. In practice, a threshold score ≥ 11 for each subscale is retained for a significant anxiety or depression score.

    Time frame: From baseline up to 12 weeks

  14. Evolution of psychiatric disorders

    Evaluation will be based on MINI-S interview (mini international neuropsychiatric interview, simplified )

    Time frame: At 12 weeks

  15. Severity of addictive disorders

    Evaluation will be based on Clinical Global Impression. The CGI includes two complementary single-item measures that assess the following: (a) severity of psychopathology on a scale of 1 to 7 and (b) change from baseline on a similar treatment on a similar seven-point scale. Following a assessment, the CGI can be completed in less than a minute by an experienced experienced assessor. The CGI is used to gather clinical impressions and track clinical clinical progress over time

    Time frame: At 12 weeks

07

Study locations

1 of 3 sites recruiting
  • CHU La Cavale Blanche
    Brest, France
    Not yet recruiting
    • Morgane Guillou, Dr · Contact
  • Centre Hospitalier Saint Jacques
    Nantes, France
    Active, not recruiting

    Not enrolling at this site.

  • CHRU De Tours
    Tours, France
    Recruiting
    • Servane BARRAULT · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2026, 15 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 15 months is below that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Jan 28, 2025
StartActual
May 13, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Oct 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06797726
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
May 13, 2025
Primary completion
Aug 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 25, 2025

Study contacts

Servane BARRAULT, Dr
Contact
s.barrault@chu-tours.fr
(+33)2.47.47.91.91
Amélie Delage
Contact
a.delage@chu-tours.fr
0247473933
Servane BARRAULT, Dr
principal investigator · CHRU de Tours
Clémence CABLEGUEN, Dr
principal investigator · Nantes University Hospital
Morgane GUILLOU, Dr
principal investigator · CHU Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion